Logo image of DH

DEFINITIVE HEALTHCARE CORP (DH) Stock Fundamental Analysis

NASDAQ:DH - Nasdaq - US24477E1038 - Common Stock - Currency: USD

2.84  +0.09 (+3.27%)

After market: 2.84 0 (0%)

Fundamental Rating

4

DH gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 37 industry peers in the Health Care Technology industry. DH scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. DH is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year DH was profitable.
DH had a positive operating cash flow in the past year.
DH had negative earnings in each of the past 5 years.
Each year in the past 5 years DH had a positive operating cash flow.
DH Yearly Net Income VS EBIT VS OCF VS FCFDH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 -100M -200M -300M -400M

1.2 Ratios

Looking at the Return On Assets, with a value of -37.92%, DH is doing worse than 70.27% of the companies in the same industry.
The Return On Equity of DH (-92.97%) is worse than 67.57% of its industry peers.
Industry RankSector Rank
ROA -37.92%
ROE -92.97%
ROIC N/A
ROA(3y)-16.45%
ROA(5y)-10.62%
ROE(3y)-39.07%
ROE(5y)-24.71%
ROIC(3y)N/A
ROIC(5y)N/A
DH Yearly ROA, ROE, ROICDH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

The Gross Margin of DH (78.30%) is better than 83.78% of its industry peers.
DH's Gross Margin has been stable in the last couple of years.
DH does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 78.3%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.22%
GM growth 5Y0.01%
DH Yearly Profit, Operating, Gross MarginsDH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

5

2. Health

2.1 Basic Checks

DH does not have a ROIC to compare to the WACC, probably because it is not profitable.
DH has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, DH has more shares outstanding
The debt/assets ratio for DH is higher compared to a year ago.
DH Yearly Shares OutstandingDH Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 50M 100M 150M
DH Yearly Total Debt VS Total AssetsDH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

DH has an Altman-Z score of 0.00. This is a bad value and indicates that DH is not financially healthy and even has some risk of bankruptcy.
DH has a Altman-Z score (0.00) which is in line with its industry peers.
The Debt to FCF ratio of DH is 5.30, which is a neutral value as it means it would take DH, 5.30 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of DH (5.30) is better than 67.57% of its industry peers.
A Debt/Equity ratio of 0.52 indicates that DH is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.52, DH is in line with its industry, outperforming 40.54% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.52
Debt/FCF 5.3
Altman-Z 0
ROIC/WACCN/A
WACC10.18%
DH Yearly LT Debt VS Equity VS FCFDH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.3 Liquidity

DH has a Current Ratio of 2.30. This indicates that DH is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 2.30, DH is doing good in the industry, outperforming 64.86% of the companies in the same industry.
DH has a Quick Ratio of 2.30. This indicates that DH is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 2.30, DH is in the better half of the industry, outperforming 67.57% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.3
Quick Ratio 2.3
DH Yearly Current Assets VS Current LiabilitesDH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

4

3. Growth

3.1 Past

DH shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 16.67%, which is quite good.
Looking at the last year, DH shows a small growth in Revenue. The Revenue has grown by 0.31% in the last year.
DH shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 24.15% yearly.
EPS 1Y (TTM)16.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%14.29%
Revenue 1Y (TTM)0.31%
Revenue growth 3Y14.91%
Revenue growth 5Y24.15%
Sales Q2Q%-5.53%

3.2 Future

DH is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -3.54% yearly.
DH is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 0.40% yearly.
EPS Next Y-37.34%
EPS Next 2Y-13.66%
EPS Next 3Y-3.54%
EPS Next 5YN/A
Revenue Next Year-6.44%
Revenue Next 2Y-1.93%
Revenue Next 3Y0.4%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
DH Yearly Revenue VS EstimatesDH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 50M 100M 150M 200M 250M
DH Yearly EPS VS EstimatesDH Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 0.1 0.2 0.3

More info and screens

6

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 8.11 indicates a reasonable valuation of DH.
97.30% of the companies in the same industry are more expensive than DH, based on the Price/Earnings ratio.
Compared to an average S&P500 Price/Earnings ratio of 28.22, DH is valued rather cheaply.
DH is valuated correctly with a Price/Forward Earnings ratio of 12.95.
Based on the Price/Forward Earnings ratio, DH is valued cheaply inside the industry as 97.30% of the companies are valued more expensively.
When comparing the Price/Forward Earnings ratio of DH to the average of the S&P500 Index (20.86), we can say DH is valued slightly cheaper.
Industry RankSector Rank
PE 8.11
Fwd PE 12.95
DH Price Earnings VS Forward Price EarningsDH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of DH indicates a rather cheap valuation: DH is cheaper than 97.30% of the companies listed in the same industry.
91.89% of the companies in the same industry are more expensive than DH, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 9.43
EV/EBITDA 4.46
DH Per share dataDH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

A cheap valuation may be justified as DH's earnings are expected to decrease with -3.54% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-13.66%
EPS Next 3Y-3.54%

More info and screens

0

5. Dividend

5.1 Amount

DH does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

DEFINITIVE HEALTHCARE CORP

NASDAQ:DH (5/2/2025, 4:30:00 PM)

After market: 2.84 0 (0%)

2.84

+0.09 (+3.27%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)02-27 2025-02-27/amc
Earnings (Next)05-08 2025-05-08/amc
Inst Owners36.9%
Inst Owner Change-0.03%
Ins Owners3.25%
Ins Owner Change33.83%
Market Cap432.50M
Analysts74.55
Price Target4.64 (63.38%)
Short Float %8.68%
Short Ratio2.99
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)15.74%
Min EPS beat(2)9.63%
Max EPS beat(2)21.86%
EPS beat(4)3
Avg EPS beat(4)6.85%
Min EPS beat(4)-4.79%
Max EPS beat(4)21.86%
EPS beat(8)6
Avg EPS beat(8)16.57%
EPS beat(12)10
Avg EPS beat(12)22.91%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-0.79%
Min Revenue beat(2)-1.38%
Max Revenue beat(2)-0.19%
Revenue beat(4)0
Avg Revenue beat(4)-1.84%
Min Revenue beat(4)-3.69%
Max Revenue beat(4)-0.19%
Revenue beat(8)0
Avg Revenue beat(8)-1.76%
Revenue beat(12)2
Avg Revenue beat(12)-1.32%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-7.14%
PT rev (3m)-13.79%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-67.65%
EPS NY rev (1m)-1.43%
EPS NY rev (3m)-27.82%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-6.49%
Revenue NY rev (1m)-0.57%
Revenue NY rev (3m)-2.8%
Valuation
Industry RankSector Rank
PE 8.11
Fwd PE 12.95
P/S 1.71
P/FCF 9.43
P/OCF 7.43
P/B 0.97
P/tB N/A
EV/EBITDA 4.46
EPS(TTM)0.35
EY12.32%
EPS(NY)0.22
Fwd EY7.72%
FCF(TTM)0.3
FCFY10.6%
OCF(TTM)0.38
OCFY13.46%
SpS1.66
BVpS2.92
TBVpS-1.62
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -37.92%
ROE -92.97%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 78.3%
FCFM 18.18%
ROA(3y)-16.45%
ROA(5y)-10.62%
ROE(3y)-39.07%
ROE(5y)-24.71%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.22%
GM growth 5Y0.01%
F-Score4
Asset Turnover0.23
Health
Industry RankSector Rank
Debt/Equity 0.52
Debt/FCF 5.3
Debt/EBITDA 5.47
Cap/Depr 23.89%
Cap/Sales 4.89%
Interest Coverage N/A
Cash Conversion 138.81%
Profit Quality N/A
Current Ratio 2.3
Quick Ratio 2.3
Altman-Z 0
F-Score4
WACC10.18%
ROIC/WACCN/A
Cap/Depr(3y)14.76%
Cap/Depr(5y)11.57%
Cap/Sales(3y)3.27%
Cap/Sales(5y)3.01%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)16.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%14.29%
EPS Next Y-37.34%
EPS Next 2Y-13.66%
EPS Next 3Y-3.54%
EPS Next 5YN/A
Revenue 1Y (TTM)0.31%
Revenue growth 3Y14.91%
Revenue growth 5Y24.15%
Sales Q2Q%-5.53%
Revenue Next Year-6.44%
Revenue Next 2Y-1.93%
Revenue Next 3Y0.4%
Revenue Next 5YN/A
EBIT growth 1Y68.48%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-13.24%
EBIT Next 3Y-2.54%
EBIT Next 5YN/A
FCF growth 1Y19.99%
FCF growth 3Y35.38%
FCF growth 5Y18.42%
OCF growth 1Y41.29%
OCF growth 3Y32.16%
OCF growth 5Y21.93%